ClinicalTrials.gg
RecruitingNCT07044596Updated Nov 4, 2026

Non-invasive Stimulation of the Glymphatic System for Slowing Cognitive Decline

An interventional study of Functional near-infrared spectroscopy (fNIRS) and V1 stimulation electrodes in Mild Traumatic Brain Injury and Post Concussion Syndrome, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to participants aged 20 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-04.

Primary conditionPost-Concussion SyndromeRegistry: Brain ConcussionReclassifiedWhy we changed it
Registry
Brain Concussion — the first condition term the registry derived for this study.
ClinicalTrials.gg
Post-Concussion Syndrome
Why
  1. The study's listed conditions name Post-Concussion Syndrome, a narrower term within Brain Concussion.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Wisconsin, Madison · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.
Updated Nov 4, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Non-randomized
Ages
20 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 77 studies in Post-Concussion Syndrome with a site in United States — 15 open to participants now, 20 under way, 1 of them phase 3. Post-Concussion Syndrome · United States.

Planned enrollment
25th of 61
55 · median 40
Started
2025
with 2 others
No phase
35 of 77
6 open now
Primary completion
2027-06
later than 8 of 19 live
Registered
67th of 77
by date

Among the 77 studies in Post-Concussion Syndrome with a site in United States, this one is the 25th largest by planned enrollment of the 61 interventional ones that give a count, is one of 3 that started in 2025, is one of 35 with no phase, reaches primary completion later than 8 of the 19 other live ones, and was the 67th registered.

Post-Concussion Syndrome

140 studies on the registry are indexed under Post-Concussion Syndrome; 33 are open to participants now.

Browse Post-Concussion Syndrome studies →

Open to participants now

15 of the 77 studies in Post-Concussion Syndrome with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 24 Post-Concussion Syndrome studies recruiting now, 3 (13%) set no upper age limit and 20 (83%) stop at 75 or younger; 2 take children under 18; 5 take healthy volunteers.

This study: 20 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 77 studies in Post-Concussion Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research is to demonstrate that mild stimulation of a nerve (trigeminal nerve) in the head can modulate blood flow in the brain. The modulated blood flow will restore the flow of cerebrospinal fluid (CSF) and this in turn can help improve waste clearance in the brain and prevent build up that may lead to disease.

Read the detailed description

The goal of this clinical trial is to demonstrate that non-invasive stimulation of the trigeminal nerve can be used to restore blood flow and consequently modulate CSF flow into the brain parenchyma to facilitate brain waste clearance that is impaired in patients with AD. This study will collect brain MRI data on 20 healthy cognitively unimpaired adults receiving intermittent trigeminal nerve branch (V1) stimulation. Participants with recent mild traumatic brain injuries will also be enrolled to establish feasibility within a clinically relevant population.

03

Conditions studied

  • Mild Traumatic Brain Injury
  • Post Concussion Syndrome

Browse trials for

04

In context

Post-Concussion Syndrome Reclassified

140 studies on the registry are indexed under Post-Concussion Syndrome; 33 are open to participants now.

This study's planned enrollment of 55 is close to the median of 52 across 113 interventional studies indexed under Post-Concussion Syndrome.

Browse Post-Concussion Syndrome studies →

Lead sponsor

University of Wisconsin, Madison is the lead sponsor of 1,190 studies on the registry; 181 are open to participants now.

Of its 157 completed or terminated interventional studies of FDA-regulated products, 118 (75%) have results posted.

Compared within Post-Concussion Syndrome, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Brain Concussion. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
20 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria - Healthy Participants :

  • Age 20-85 years
  • Willing and able to undergo all procedures
  • Free of any neurological (e.g., epilepsy, stroke, Parkinson's, brain tumors, moderate or severe traumatic brain injury), neuropsychiatric (e.g., schizophrenia, substance abuse, clinical depression), or developmental (e.g., autism, ADHD) or any other medical condition at the discretion of the PI and co-investigators

Inclusion Criteria - mTBI :

  • Age 20-65
  • Diagnosed with mild traumatic brain injury and be within 1-52 weeks post-injury
  • Willing and able to undergo all procedures

Exclusion Criteria - Healthy Participants:

  • to MRI
  • Known allergies to common electrode materials

Exclusion Criteria - mTBI:

  • Contraindications for MRI
  • Known allergies to common electrode materials
  • Candidates currently on cardiovascular medications which, in the opinion of the investigators, would introduce a confounding factor to glymphatic system function (i.e. ACE-inhibitors, angiotensin receptor blockers, calcium channel blockers)
  • Candidates who have chronic infectious diseases (e.g. hepatitis, , TB)
  • Candidates diagnosed with small vessel disease, vascular associated dementia (e.g. VCID), or renal disease
  • Candidates retinopathies or neuropathies that, in the opinion of the investigators, would prevent them from being able to complete the study or would introduce a confounding factor to glymphatic system function
  • Candidates with neurological disorders other than those attributed to their primary diagnosis (e.g. MS, PD, ALS, AD or other dementia, uncontrolled pain)
  • Candidates who have had a penetrating injury, craniotomy (with the exception of a burr hole (trephination) for resolution of acute subdural hematoma), or subdural hematoma
  • Candidates with a history of seizures (except those in the acute or post-acute phases and are controlled)
  • Candidates who experienced a loss of consciousness greater than 24 hours as a result of their TBI
  • Candidates who, in the opinion of the investigators, are unable to feel a sensory referred sensation from the stimulation or successfully complete the electrode placement and testing fNIRs
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (estimated)

Study arms

  • Active comparator
    Healthy Controls

    Device: Functional near-infrared spectroscopy (fNIRS) · Device: V1 stimulation electrodes · Device: Magnetic Resonance Imaging (MRI) · Device: MAGNUS scanner

  • Active comparator
    Mild traumatic brain injury (mTBI)

    Participants with recent mTBI

    Device: Functional near-infrared spectroscopy (fNIRS) · Device: V1 stimulation electrodes · Device: Magnetic Resonance Imaging (MRI)

Interventions

  • DeviceFunctional near-infrared spectroscopy (fNIRS)

    fNIRS is a non-invasive imaging technique which takes advantage of the light scattering and absorption differences between oxygenated (HbO) and de-oxygenated hemoglobin (HbDO) to characterize changes in cerebral hemodynamics in response to a given task or stimulus.

  • DeviceV1 stimulation electrodes

    The V1 electrodes will be placed on the forehead with some gel and held in place with a headband or cap (a conductive adhesive gel may be placed under the electrodes to help with stimulation). Participants will receive short electrical stimulations through these electrodes that will differ in intensity.

  • DeviceMagnetic Resonance Imaging (MRI)

    Participants will undergo 2 90-minute MRI sessions

  • DeviceMAGNUS scanner

    Simultaneous Coherent-Incoherent Motion Imaging (SCIMI) available on the MAGNUS scanner will be used to perform quality control and optimization in healthy volunteers, to better resolve and visualize slow CSF flows within the brain.

    Also known as: GE-MAGNUS 3T MRI scanner

07

What researchers measure

Primary outcomes

  1. Change in blood flow through the brain parenchyma - fNIRS

    The fNIRS device will record changes in the blood oxygen level in the brain that is caused by the V1 stimulation.

    Time frame: Baseline to 4 hours

  2. Change in blood flow through the brain - MRI

    The MRI will record changes in the blood oxygen level in the brain that is caused by the V1 stimulation.

    Time frame: Baseline to 90 minutes

  3. Change in cerebrospinal fluid flow

    MRI scan will be used to measure the flow of cerebrospinal fluid before, during and after stimulation.

    Time frame: Baseline to 90 minutes

08

Study locations

1 of 1 sites recruiting
  • University of Wisconsin - Madison
    Madison, Wisconsin 53705, United States
    Recruiting
    • Kip Ludwig, PhD · Principal investigator
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Jun 2027, 19 months after the start.

Of 54 non-industry interventional studies with no phase under Post-Concussion Syndrome, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 58. This study's planned 19 months is below that.

Counting every sponsor, half of 56 studies reached it within 40 months; a quarter within 23 and three quarters within 69.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: primary completion Dec 2026 → Jun 2027 and completion Dec 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2025
First posted
Jul 1, 2025
StartActual
Nov 13, 2025
Primary completionEst.
Jun 2027was Dec 2026
CompletionEst.
Jun 2027was Dec 2026
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Jun 2027
Nov 4, 2026
Study completion
Dec 2026→Jun 2027
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Primary completion Dec 2026→Jun 2027
    Study completion Dec 2026→Jun 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07044596
Collaborators
Neuraworx Medical Technologies
Responsible party
Sponsor
First posted
Jul 1, 2025
Start date
Nov 13, 2025
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Neurosurgery Research
Contact
research@neurosurgery.wisc.edu
608-261-1577
Kip Ludwig, PhD
principal investigator · University of Wisconsin, Madison

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion